The FDA has granted full approval for Avastin® (bevacizumab)
The FDA has granted full approval for Avastin® (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy (referred to as recurrent disease). Avastin was previously granted provisional approval in this setting under the FDA’s accelerated approval program. The Genentech press release, which includes Important Safety Information is available at this link.
